[
  {
    "ts": "2025-11-10T09:00:00+00:00",
    "headline": "UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)",
    "summary": "REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) against Alvotech and its contract manufacturing organization (CMO) in the United Kingdom. The court rejected Regeneron’s and Bayer’s injun",
    "url": "https://finance.yahoo.com/news/uk-high-court-rules-favor-090000360.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "a7683f5d-6525-3fef-a31b-ff14cb1f8d54",
      "content": {
        "id": "a7683f5d-6525-3fef-a31b-ff14cb1f8d54",
        "contentType": "STORY",
        "title": "UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)",
        "description": "",
        "summary": "REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) against Alvotech and its contract manufacturing organization (CMO) in the United Kingdom. The court rejected Regeneron’s and Bayer’s injun",
        "pubDate": "2025-11-10T09:00:00Z",
        "displayTime": "2025-11-10T09:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/8a0f73734c0720ca8ced92018fd212e7",
          "originalWidth": 1045,
          "originalHeight": 364,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zXNKkkhZMap5mi1BfvNTKw--~B/aD0zNjQ7dz0xMDQ1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/8a0f73734c0720ca8ced92018fd212e7.cf.webp",
              "width": 1045,
              "height": 364,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1ZbnWrzrsTTPjuDyQZ978Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8a0f73734c0720ca8ced92018fd212e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/uk-high-court-rules-favor-090000360.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/uk-high-court-rules-favor-090000360.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALVO"
            },
            {
              "symbol": "ALVOW"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "BAYN.DE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T11:56:54+00:00",
    "headline": "Dupixent set for ninth US approval after Phase III AFRS success",
    "summary": "Patients treated with Dupixent were 92% less likely to need corticosteroids or surgery.",
    "url": "https://www.clinicaltrialsarena.com/news/dupixent-set-for-ninth-us-approval-after-phase-iii-afrs-success/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "6c1d251e-ac2d-3c78-a721-7ac4f0b79223",
      "content": {
        "id": "6c1d251e-ac2d-3c78-a721-7ac4f0b79223",
        "contentType": "STORY",
        "title": "Dupixent set for ninth US approval after Phase III AFRS success",
        "description": "",
        "summary": "Patients treated with Dupixent were 92% less likely to need corticosteroids or surgery.",
        "pubDate": "2025-11-10T11:56:54Z",
        "displayTime": "2025-11-10T11:56:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/dupixent-set-for-ninth-us-approval-after-phase-iii-afrs-success/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dupixent-set-ninth-us-approval-115654451.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T17:22:14+00:00",
    "headline": "European Equities Close Sharply Higher in Monday Trading on Hopes for End to US Government Shutdown",
    "summary": "European stock markets surged in Monday trading on investor optimism that the end of the US governme",
    "url": "https://finance.yahoo.com/news/european-equities-close-sharply-higher-172214637.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "8a778143-1309-3481-8729-99aba2c721bc",
      "content": {
        "id": "8a778143-1309-3481-8729-99aba2c721bc",
        "contentType": "STORY",
        "title": "European Equities Close Sharply Higher in Monday Trading on Hopes for End to US Government Shutdown",
        "description": "",
        "summary": "European stock markets surged in Monday trading on investor optimism that the end of the US governme",
        "pubDate": "2025-11-10T17:22:14Z",
        "displayTime": "2025-11-10T17:22:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/european-equities-close-sharply-higher-172214637.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/european-equities-close-sharply-higher-172214637.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALVO"
            },
            {
              "symbol": "CBK.DE"
            },
            {
              "symbol": "BNP.PA"
            },
            {
              "symbol": "BAYN.DE"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]